G6PD

Medical Analysis

Comprehensive Overview of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme within the hexose monophosphate shunt pathway [1, 9]. Abnormalities in this pathway or in glutathione metabolism, resulting from impaired or deficient enzyme function, significantly reduce the ability of red blood cells (RBCs) to protect themselves against oxidative injuries [2, 14]. This vulnerability leads to hemolytic disease [2, 3]. G6PD deficiency is inherited as an X-linked recessive genetic disorder that specifically affects RBCs, resulting in either reduced or entirely absent enzyme activity [3, 9]. Furthermore, specific G6PD mutations can directly lead to this enzyme deficiency [10].

Mechanisms of Hemolysis in G6PD Deficiency

The pathophysiology of hemolysis in G6PD-deficient individuals follows a specific sequence [2, 3]. G6PD deficiency causes low enzyme levels, which impairs the protective mechanisms of red blood cells [2]. Consequently, oxidative stress damages these cells [9, 14]. The damaged cells frequently form Heinz bodies and undergo structural changes, appearing as “bite cells” on peripheral blood smears [2, 11]. These fragile cells are prone to premature breakdown, leading to episodes of hemolytic anemia [2, 14]. Key triggers for these hemolytic episodes include specific infections, medications, and certain foods [2, 7].

Genetics, Inheritance, and Biological Functions

G6PD deficiency is categorized as an X-linked recessive disorder, making it significantly more common in males [3, 11]. It exhibits a high prevalence across African, Mediterranean, and Asian populations [6, 8]. Functionally, G6PD maintains the integrity of RBCs by generating NADPH [3, 14]. It catalyzes the conversion of G6PD to 6-phosphogluconate, which produces NADPH [9]. This molecule is crucial for glutathione reduction; NADPH helps keep glutathione in a reduced form, which neutralizes reactive oxygen species and protects cells from oxidative damage [2, 14]. By maintaining this redox balance, the enzyme prevents the premature destruction of red blood cells [3, 11].

Clinical Triggers and Diagnostic Indicators

Hemolytic episodes are often precipitated by external factors categorized as follows:

Common clinical indicators and symptoms of G6PD deficiency include pale or yellow skin, jaundice, dark tea-colored urine, tachycardia, shortness of breath, fatigue, enlarged spleen, and back pain [2, 11]. Laboratory investigations may reveal hemolytic anemia, a raised reticulocyte count, a positive Coombs test, and the presence of dark urine [2, 4].

Diagnostic Testing and Reference Ranges

Sample collection involves obtaining 1.0 mL of blood in an EDTA container, which is the preferred anticoagulant for G6PD testing as it preserves enzyme stability for up to 72 hours when stored at 4°C [11]. Alternative collection methods include ACD, CPD, sodium citrate, and lithium heparin [11]. Available assays include quantitative G6PD enzyme assays, qualitative G6PD enzyme assays, and genetic screening [4, 11].

For calculating G6PD values, one must estimate both G6PD activity and total hemoglobin [11]. G6PD activity is typically calculated by determining the change in absorbance at 550 nm over 12 minutes, multiplying by a dilution factor, and dividing by the absorbance reading at 405 nm, or by following specific kit instructions [11].

Reference Ranges (U/g Hb)

Haematological Findings and Clinical Significance

Haematological examination often reveals the presence of Heinz bodies in RBCs, bite cells (degmacytes) on peripheral blood smears (PBS), reticulocytosis, elevated indirect bilirubin, and elevated LDH levels [2, 11]. The RDW is typically normal or mildly elevated [11]. Between hemolytic crises, the blood count is often normal [2, 11].

Clinical significance is categorized by enzyme activity levels [11]:

• Severe Deficiency (< 10% of normal range): Patient presents with features of chronic hemolytic anemia [11].

• Moderate Deficiency (10–60% of normal range): Patient presents with features of intermittent hemolytic anemia triggered by antibiotics, antimalarial drugs, infections (bacterial or viral), certain foods, or pollen [2, 7, 11].

Management focuses on the early diagnosis of the condition and the strict avoidance of known triggers to prevent the onset of symptoms [4, 14].

For Non-Medicos: Understanding G6PD Deficiency

G6PD deficiency is a common genetic condition that affects your red blood cells [6, 9]. To understand it, think of your red blood cells as delivery trucks carrying oxygen around your body [11]. These trucks are constantly exposed to “rust” (oxidative stress) from your environment, diet, and medications [2]. G6PD is an enzyme that acts like a protective coating or a “rust-proofing” agent for these cells [2]. If you have a deficiency, your red blood cells lack this protection, making them very fragile and prone to breaking down prematurely [3, 14].

What Happens During a Crisis?

When a person with G6PD deficiency encounters certain triggers—such as fava beans, specific antibiotics, or infections—the “rust” builds up too quickly [2, 7]. The red blood cells become damaged, develop tiny bumps (Heinz bodies), and get chewed up by the spleen (creating “bite cells”) [2]. When many cells break down at once, this is called a hemolytic crisis [14]. This leads to symptoms like jaundice (yellowing of the skin/eyes), dark tea-colored urine, extreme tiredness, and shortness of breath [2, 11].

Key Things You Should Know

• It’s Genetic: This condition is passed down through families [3]. It is much more common in men than in women [11].

• Avoid Triggers: The most important way to manage this is to avoid the things that cause your red blood cells to break down [4, 14]. This includes certain medications (like some malaria drugs or aspirin in high doses), fava beans (sometimes called “favism”), and certain chemicals like naphthalene (mothballs) [7, 11].

• Diagnosis: If you have symptoms, doctors can confirm G6PD deficiency with a simple blood test [4]. It is best to have this done when you are not currently having a crisis, as the results can be more accurate [11].

• Management: While there is no “cure” to replace the enzyme, living a healthy life and knowing what triggers your symptoms allows most people to live completely normal lives [14]. Always tell your doctor about this condition before taking new medications [4, 7].

References:

1. Beutler, E. (1994). G6PD deficiency. Blood, 84(11), 3613-3636.

2. Cappellini, M. D., & Fiorelli, G. (2008). Glucose-6-phosphate dehydrogenase deficiency. The Lancet, 371(9606), 64-74.

3. Luzzatto, L., Nannelli, C., & Notaro, R. (2020). Glucose-6-phosphate dehydrogenase deficiency. Hematology/Oncology Clinics, 34(2), 373-393.

4. Frank, J. E. (2005). Diagnosis and management of G6PD deficiency. American Family Physician, 72(7), 1277-1282.

5. Mason, P. J., Bautista, J. M., & Gilsanz, F. (2007). G6PD deficiency: the clinical and molecular basis. British Journal of Haematology, 138(6), 711-726.

6. Nkhoma, E. T., Poole, C., Vannappagari, V., et al. (2009). The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. Blood Cells, Molecules, and Diseases, 42(3), 267-278.

7. Youngster, I., Arcavi, L., Schechmaster, R., et al. (2010). Medications and glucose-6-phosphate dehydrogenase deficiency: An evidence-based review. Drug Safety, 33(9), 713-726.

8. Howes, R. E., Piel, F. B., Patil, A. P., et al. (2012). G6PD deficiency prevalence and global distribution of clinical burden. PLoS Medicine, 9(11), e1001339.

9. Mehta, A., Mason, P. J., & Vulliamy, T. J. (2000). Glucose-6-phosphate dehydrogenase deficiency. Baillière’s Best Practice & Research Clinical Haematology, 13(1), 21-38.

10. Minucci, A., Moradkhani, K., Hwang, M. J., et al. (2012). Glucose-6-phosphate dehydrogenase (G6PD) mutations database: Review of the “old” and update of the new mutations. Blood Cells, Molecules, and Diseases, 48(3), 154-165.

11. Glader, B. (2014). Glucose-6-phosphate dehydrogenase deficiency. Nelson Textbook of Pediatrics, 20th Edition.

12. WHO Working Group. (1989). Glucose-6-phosphate dehydrogenase deficiency. Bulletin of the World Health Organization, 67(6), 601-611.

13. Beutler, E. (1991). The G6PD deficiency: A historical perspective. Blood, 77(1), 1-8.

14. Manganelli, S., & Fico, A. (2015). G6PD deficiency: A review of the current status. Journal of Blood Medicine, 6, 233-242.

FAQ’s:

• What is G6PD deficiency?
  It is a genetic disorder affecting red blood cell enzyme activity, leading to premature cell breakdown.

• How is G6PD inherited?
  It is inherited as an X-linked recessive disorder, making it significantly more common in males.

• What triggers a hemolytic crisis?
  Triggers include specific infections, certain medications like aspirin, fava beans, and various chemical exposures.

• What are the main symptoms?
  Symptoms include jaundice, pale skin, fatigue, dark tea-colored urine, and shortness of breath.

• How is the condition diagnosed?
  Diagnosis involves a blood test to measure G6PD enzyme activity and total hemoglobin levels.

• What blood sample is required?
  A 1.0 mL blood sample collected in an EDTA container is used for the testing.

• Does it cause kidney problems?
  While primarily causing hemolytic anemia, associated conditions can impact overall health and renal function.

• Are there different severity levels?
  Yes, severity ranges from severe (<10% activity) to moderate (10-60% activity) enzyme levels.

• What are bite cells?
  They are damaged red blood cells formed due to oxidative stress, visible on blood smears.

• How is the condition managed?
  Management focuses on early diagnosis and strictly avoiding known triggers to prevent symptom onset.